The humanitarian crisis in Gaza is putting an extra burden on the already fragile state of diabetes management for all people with diabetes in the Strip. I had witnessed the situation myself many times before and contacted friends living with diabetes and healthcare professionals. I can assure you that people are suffering. Read more
To kick off Diabetes Awareness Month, the Global Diabetes compact held a two-day meeting where T1International and 35 other organisations in over 25 countries presented the goal of the Fight for Five campaign. We showed the depth and breadth of support for this campaign not only through stories of patients most impacted by lack of affordable and accessible insulin in their home countries, but also by the number of organisations that support a better world for people with diabetes. Read more
Mridula Kapil Bhargava began advocating to end diabetes stigma and for #insulin4all in 2015. As a Global Advocacy Partner representative of T1International (through Diabetes Fighters Trust) as well as a member of our Fight for Five Working Group, Mridula plays a huge role in our efforts to fight for a world where no one has to spend more than 5% of their average income for the insulin they need to survive and achieve their dreams. Read more
As I listened to the amazing sessions at this year's Summit, the rage from 2016 was still there, and rightly so, but there was also so much love, inclusivity and power. Whether you like the term 'patients' or not - we debated it at the Summit - this event was full of patients taking back their power. I was proud to be part of it and continue to be proud that T1International is making such a huge global impact as a small, pharma-free charity. Read more
Over the past few months, many insulin manufacturers and other entities have announced that they will be lowering the price of insulin in the United States. So, why is insulin still so expensive?
We recently released our Policy Playbook that goes through all of the details and gives advocates the information to push for change locally and nationally. Why insulin is so expensive can be boiled down to three main points. Read more
Mohammed Seyam has been leading T1International's Middle East and North Africa (MENA) Region Chapter since 2021 but has been advocating for himself and his community for much longer. As a medical doctor with type 1 diabetes, he is on a mission to break down barriers to healthcare and education. Mohammed has always been motivated by his community and uses his lived experience to influence his work. Read more
We are pleased to announce that the 2023 WHO EML, released yesterday, now includes disposable and reusable pens with cartridges for human insulin. You may remember that two years ago, T1International’s advocacy was instrumental in the WHO’s decision to add long-acting insulin analogues in vials and pens to its EML. This week’s decision paves the way for short-acting insulin analogues to be added to the WHO EML in 2025 in both vial and pen preparations. Read more
On March 1, Eli Lilly announced it would reduce the list prices of some of its insulins, including the generic Lispro, the same product as the name-brand Humalog. At a recent congressional hearing with the CEOs of insulin manufacturers and pharmacy benefit managers, David Ricks, Eli Lilly’s CEO, again celebrated that $25 insulin lispro was available to patients as of May 1. People with diabetes have worked tirelessly to reduce insulin costs for decades. So why aren’t we universally celebrating this announcement of lower prices? Because it is now the end of May, and I - and many others in my community - still haven’t been able to get the promised $25 insulin.
Advocates recently gathered in Washington, DC to attend the Senate HELP Committee Hearing entitled: The Need to Make Insulin Affordable for All Americans. The hearing, led by Chairman Senator Bernie Sanders, is the culmination of a decade of advocacy efforts by the #insulin4all community who have demanded public accountability for the global insulin price crisis. Read more
In 2017, our Global Partner Representative, Pilar moved from the UK to Panama and discovered a stark difference in reality when it came to healthcare. Pilar realised that diabetes care and education within Panama was nowhere near as accessible as it was in the UK and that this was leading to inadequate care for patients, particularly children.